HK Stock Market Move | LEPU BIO (02157) rose more than 6% in the afternoon, MRG006A has shown excellent clinical data for the treatment of advanced liver cancer in Phase I.

LEPU BIO (02157) rose more than 6% in the afternoon, up 4.74% as of the time of publication, at HKD 3.98, with a turnover of HKD 41.495 million. In terms of news, Lepu Bioscience's phase I clinical trial data for MRG006A targeting advanced liver cancer patients who have failed standard treatment, disclosed at ASCO 2026, is quite excellent. MRG006A enters the liver cancer field where no ADC has been approved globally, representing a new path that has not been fully developed yet and has already passed the clinical verification threshold. This indicates that it could potentially become the next Chinese first-in-class ADC project with BD imaginative space. It is worth noting that Lepu Bioscience has announced that its self-developed antibody-drug conjugate targeting CDH17, MRG007, has officially received acceptance for new drug clinical trial application from the National Medical Products Administration's Drug Evaluation Center. This new clinical acceptance marks a key milestone in its clinical development in the field of digestive tract tumors, and it is expected to bring a brand new treatment option for millions of advanced digestive tract tumor patients in China in the future.